Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

PEMGARDA™ (pemivibart) net product revenue of $13.8 million, 48% growth over Q3 2024 net product revenue of $9.3 ...

Half-Life and Doom are remembered as the defining games of the FPS golden era, but one vicious and vivid shooter deserves the ...

After years of waiting, fans are finally confident that Half-Life 3 is real and coming soon. I count myself among their numbers — enough signs point to the long-awaited, once-cancelled sequel being in ...

The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

Two of three technologies featured at Sarasota event rely on plant-based chemicals; the third uses water cavitation, ozone ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS ...

The FDA approved an oral combination of meloxicam and rizatriptan (Symbravo) to treat adults with acute migraine with or ...

The climate has changed in the past, long before humans, so how do scientists know our recent warming is caused by man?

Bicycle Therapeutics' BT8009 offers strong safety and efficacy. Find out why BCYC stock could be a buy, despite recent volatility and awaiting mid-2025 data.